Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6426509 | 0.92 | TDP1 (0.38) | TDP1EGLN1MAPK1SLC13A3OR51E2 | |
| SCHEMBL15391983 | 0.78 | MMP1 (0.48) | EGLN1MAPK1SLC13A3OR51E2FOLH1 | |
| SCHEMBL6008457 | 0.76 | EGLN1 (0.39) | TDP1EGLN1MAPK1SLC13A3OR51E2 | |
| SCHEMBL3472426 | 0.75 | TDP1 (0.45) | TDP1MAPK1FOLH1LMNAMMP1 | |
| SCHEMBL17402240 | 0.75 | TDP1 (0.45) | TDP1LMNAMMP1MMP2MMP3 | |
| SCHEMBL7828547 | 0.74 | TDP1 (0.31) | TDP1 | |
| SCHEMBL8127304 | 0.73 | TDP1 (0.52) | TDP1FOLH1LMNAMMP1MMP2 | |
| SCHEMBL9616895 | 0.73 | TDP1 (0.52) | TDP1FOLH1LMNAMMP1MMP2 | |
| SCHEMBL21456762 | 0.72 | TDP1 (0.50) | TDP1MMP1MMP2MMP3MMP9 | |
| SCHEMBL9995363 | 0.70 | TDP1 (0.48) | TDP1LMNAMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177548-A1 | Methods and Compositions for Treating Melanoma | WISTAR INST (US) | 2022-06-09 | — | — | US | disclosed |
| US-11208468-B2 | Methods and compositions for treating melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190276517-A1 | Methods and Compositions for Treating Melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2019-09-12 | — | — | US | disclosed |
| US-7811993-B2 | Methods and compositions for treating melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100203109-A1 | Methods and Compositions for Treating Melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2010-08-12 | — | — | US | disclosed |
| US-7189691-B2 | Methods and compositions for treating leukemia | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2007002811-A2 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050222012-A1 | Methods and compositions for treating leukemia | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2005-10-06 | — | — | US | disclosed |
| US-20030064918-A1 | Compounds and uses thereof in treating bone disorders | AUCKLAND UNISERVICES LIMITED, NEW ZEALAND CORPORATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064918-A1 | Compounds and uses thereof in treating bone disorders | BMP2, SOST, BMP6 | TDP1 4369/4885EGLN1 764/4885MAPK1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.